Carbohydrate key to C. diff vaccine

German researchers have synthesized a carbohydrate on the surface of an extremely virulent strain of Clostridium difficile, a potentially deadly hospital-acquired infection, that could lead to a vaccine for the difficult-to-treat disease. Max Planck Institute scientists hope that they can develop a vaccine based on the carbohydrate that enables the body to recognize and respond to the threat of infection. Article

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.